Latest in Digestion

How to leverage the gut-skin axis to address health conditions

Food supplements: a better way to utilise the body’s microbiome? Stuart J. Ashman, CEO, and Dr Catherine O’Neill, CSO, SkinBioTherapeutics, investigate

Find out more

Omron and Cognizant to offer IT/OT integration services to pharmaceutical manufacturers

Together, Omron and Cognizant will help manufacturers to integrate IT-OT into their operations and maintenance processes
See more

DuPont enters microbiome therapy collaboration with MRM Health

MRM has raised more than $15m to advance its clinical and preclinical development programmes

Kaleido joins forces with Janssen on microbiome metabolic therapies

Janssen and Kaleido have agreed to explore the potential of microbiome metabolic therapies to prevent onset of childhood allergy and other atopic, immune and metabolic conditions

LNC Therapeutics forms advisory board for Christensenella research

The gut microbiome-based drug research and discovery specialist has chosen experts to advise the future of its Christensella R&D programme

New microbiome specialist raises $82m and partners with Thermo Fisher

Arranta Bio will have access to Thermo Fisher’s full suite of products and services and will provide materials to Thermo Fisher for use in gene therapy production

Tillotts signs IBD research agreement

Discovery efforts with LabGenius to identify and develop new drug candidates for the treatment of inflammatory bowel diseases

Berberine enhances antibiotic treatment of Helicobacter pylori

<i>Helicobacter pylori</i> are Gram-negative bacteria that inhabit the gastric mucosa and are associated with peptic ulcers and gastric malignancy

Collaboration to develop novel microbial therapy for UC

Microbiotica has entered into an agreement with the University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis

Preparing for the future of contained oncology drug production

Advancements in oncology drug production, containment technologies, and automation have manifestly improved the safety, efficiency, and precision aspects of manufacturing highly potent cancer treatments

Latest posts in Digestion

Microbiotica enters into microbiome collaboration with Genentech

Microbiotica, a leading player in microbiome-based therapeutics, has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD)

UK biotech to manufacture novel IBD medicines using gut bacteria spores

Chain Biotech, Porton Biopharma and Scitech have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions such as ulcerative colitis and Crohn’s disease through interaction with the human microbiome

Sobi Orfadin capsules approved in Saudi Arabia

Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1

Catalent provides manufacturing for carcinoid syndrome drug

Manufacturing of the Lexicon Pharmaceuticals' orphan drug follows recent US Food and Drug Authority approval

Cypralis awarded new funding by Innovate UK

The life sciences company has been granted new UK early stage award to develop cyclophilin D inhibitors, targeting degenerative diseases

Prokarium and Probiomed in UK-Mexico collaboration to manufacture thermostable vaccines

Prokarium and Probiomed have announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40 °C for several weeks

Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastrointestinal disorders

Sosei Group announces that its subsidiaries, Heptares and Jitsubo Co., Ltd, and have entered into a collaboration to develop novel peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastrointestinal (GI) disorders

Certara receives FDA grant to simulate drug behaviour in the GI tract

The new models will predict and simulate the behaviour of supersaturating orally dosed drug products in the human GI tract

Exponential growth on the cards for the microbiome industry

The microbiome market could be as big as biotech in the next 20 years, reports Dr Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners

Generics expand into GI markets, spurring growth

The generic versions of various expiring blockbuster drugs are keying growth in the gastrointestinal therapeutics and diagnostic markets

Galenica completes acquisition of Relypsa

Combination with Relypsa strengthens Vifor Pharma's position as a leading specialty pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa

Recipharm establishes long-term supply agreement with Tillotts Pharma

Swedish CDMO will handle technology transfer and commercial manufacturing of gastro-enterology products

Sponsor content

Therapeutic: cobitolimod for ulcerative colitis

The inflammatory bowel disease ulcerative colitis is a chronic immune-mediated condition that affects the colon and rectum

Drug delivery solution for the treatment of gastrointestinal disorders

Quay Pharma has developed a specialised filling system to enable a new treatment for anorectal diseases to enter Phase III clinical trials

New room-temperature stable Carglunic acid tablets

Carglumic acid is a therapeutic tool in the management of inborn metabolic disorders affecting the urea cycle

RedHill Biopharma announces exclusive US co-promotion agreement with Concordia for GI drug Donnatal

RedHill and Concordia have entered into an exclusive co-promotion agreement, granting RedHill certain US promotion rights for Donnatal